Grail is a biotechnology company founded in 2016 by Jeffrey Huber, Sjuul van den Eertwegh, and is headquartered in Menlo Park, California. Grail is developing a blood test capable of detecting early stage cancer.
On May 31, 2017 Grail merged with a Chinese startup called Cirna to help expand its global production capacity. Cirina, which was founded by Dennis Lo of the Chinese University of Hong Kong and raised $12 million in a Series A financing round in 2014, will operate as a subsidiary of Grail.
On January 12, 2016 Grail closed their series A funding round with $100 million in funding from Illumina, Stutter Hill Ventures, Biomatics Capital Partners, Bezos Expeditions, ARCH Venture Partners, and Bill Gates.
On November 22, 2017 Grail closed their series B funding round with $1.2 billion in funding from ARCH Venture Partners, Johnson & Johnson Development Corporation, and Glen Kacher.
On May 21, 2018 Grail closed their series C funding round with $300 million in funding from WuXi NextCode, Sequoia Capital China, IBC International, HuangPu River Capital, Hillhouse Capital Group, China Merchants Securities, Blue Pool Capital, Ally Bridge Group, and 6 Dimensions Capital.
Vice President of Research & Development
Vice President of Clinical Development
Vice President of Corporate Affairs
Vice President of People
President & Head of Corporate Development and Strategy
Vice President of Product Marketing
General Counsel and Corporate Secretary
Vice President of Biostatistics & Data Management
The $1 billion bet on the perfect cancer test
What You Need to Know About GRAIL | BioSpace
Documentaries, videos and podcasts